![Valerie Odegard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Valerie Odegard
Direktor/Vorstandsmitglied bei
ODYSSEY THERAPEUTICS, INC.
Vermögen: - $ am 30.09.2026
Profil
Dr. Valerie Odegard is a Chief Executive Officer at Dovetail Therapeutics, Inc., a Venture Partner at OrbiMed Advisors Private Equity and an Independent Director at Odyssey Therapeutics, Inc. She is on the Board of Directors at Odyssey Therapeutics, Inc. and Abata Therapeutics, Inc. Dr. Odegard was previously employed as a President & Chief Scientific Officer by Silverback Therapeutics, Inc. and a Vice President-Research by Juno Therapeutics, Inc. She received her undergraduate degree from Wake Forest University and a doctorate degree from Yale University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 08.05.2026 | 0 ( -.--% ) | - $ | 30.09.2026 |
Aktive Positionen von Valerie Odegard
| Unternehmen | Position | Beginn |
|---|---|---|
| ODYSSEY THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.10.2021 |
Abata Therapeutics, Inc.
 Abata Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treg cell therapies for serious autoimmune and inflammatory diseases | Direktor/Vorstandsmitglied | 29.07.2021 |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Private Equity Investor | 01.10.2022 |
Ehemalige bekannte Positionen von Valerie Odegard
| Unternehmen | Position | Ende |
|---|---|---|
| ARS PHARMACEUTICALS, INC. | Präsident | 02.09.2022 |
| JUNO THERAPEUTICS INC | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2016 |
Ausbildung von Valerie Odegard
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
64
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Wake Forest University
 Wake Forest University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Finance |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
Silverback Therapeutics, Inc.
 Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for autoimmune and inflammatory diseases | Health Technology |
Abata Therapeutics, Inc.
Abata Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treg cell therapies for serious autoimmune and inflammatory diseases | Health Technology |
